Caring for Our Future: Excellence in Paediatric Care
At Geistek Pharmaceuticals, we are deeply committed to the health and well-being of children. Our focus on paediatrics drives us to deliver exceptional care, innovative treatments, and cutting-edge research to improve the lives of young patients around the world.
With a dedicated team of paediatric experts, we understand the unique needs and challenges faced in paediatric care. From infancy through adolescence, we strive to provide comprehensive and compassionate healthcare that supports the growth, development, and overall well-being of children.
Our commitment to paediatrics extends to a wide range of specialties, including but not limited to cardiology, neurology, endocrinology, pulmonology, and infectious diseases. Through our collaborative efforts with leading paediatricians, researchers, and healthcare institutions, we are at the forefront of advancing paediatric medicine and developing tailored treatments for young patients.
Geistek Pharmaceuticals conducts clinical trials and research studies specifically designed for paediatric populations. Our goal is to improve treatment options, optimize medication dosing, and ensure the safety and efficacy of therapies for children. By involving paediatric patients in clinical research, we can better understand their unique responses to treatments and develop interventions that cater to their specific needs.
We believe in a holistic approach to paediatric care that not only focuses on medical treatment but also emphasizes emotional support for children and their families. We work closely with parents, caregivers, and the paediatric community to provide educational resources, support programs, and a nurturing environment that promotes the best possible outcomes for young patients.
As we continue to advance paediatric care, we remain dedicated to maintaining the highest standards of safety, ethics, and regulatory compliance. We adhere to rigorous protocols and guidelines to ensure the well-being of our young patients and provide parents with peace of mind.
INTRODUCTION Tecartus is a new advanced therapy approved to treat adults with mantle cell lymphoma (MCL)¹. This disease is a lymphatic system cancer. Specifically, it
INTRODUCTION Kymriah (Novartis) is an advanced therapy medicine that belongs to the gene therapyproduct category. It is approved for B-cell acute lymphoblastic leukemia (ALL) in
INTRODUCTION ¹. CARVYKTI™ (ciltacabtagene autoleucel – Johnson & Johnson) was approved by the U.S. Food and Drug Administration (FDA) in February 2022 for the treatment
